[{"orgOrder":0,"company":"Sentien Biotechnologies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sentien Biotechnologies Announces Open IND in Phase 1\/2 Trial of SBI-101 for Patients with COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I\/ Phase II","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"August 2020","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II"},{"orgOrder":0,"company":"Sentien Biotechnologies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sentien Biotechnologies Announces First Subject Dosed in Phase 1\/2 Trial of Ex Vivo MSC Therapy for the Treatment of Severe COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I\/ Phase II","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"November 2020","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II"}]
Find Clinical Drug Pipeline Developments & Deals by Sentien Biotechnologies
First subject has been enrolled in Sentien's Phase 1/2 study of SBI-101 trial. SBI-101 is a cell-based therapy, is being evaluated in COVID-19 patients suffering from both acute respiratory distress syndrome and acute kidney injury (AKI) requiring renal replacement therapy.
Lead Product(s):
Allogeneic mesenchymal stromal cells
Approval of this IND allows Sentien to initiate a Phase 1/2 study with a focus on COVID-19 patients suffering from both acute respiratory distress syndrome (ARDS) and acute kidney injury (AKI) requiring renal replacement therapy (RRT).